Location: Jackson, TN; Orlando, FL
Indication: Atopic Dermatitis and Healthy Controls
Sponsor: Precision Biospecimen Solutions, Inc.
PI: Dafnis Carranza, MD; Christopher Chappel, MD
Intervention/Treatment: Biospecimen collection
Ages: 18+
Criteria:
- Subjects with a documented diagnosis of Atopic Dermatitis
- Diagnosis must be within one year
- Healthy subjects without a diagnosis of Atopic Dermatitis or generalized dermatology conditions
Compensation: You may be compensated for your time and participation
Location: Jackson, TN
Indication: Plaque Psoriasis
Sponsor: Nimbus Lakshmi, Inc.
PI: Dafnis Carranza, MD
Intervention/Treatment: NDI-034858 (Oral)
Ages: 18-70
Criteria:
• Must have a history of plaque psoriasis for at least 6 months
• Must have moderate to severe plaque psoriasis
• Must have NO significant flare is psoriasis for at least 3 months
• Must NOT have a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessment
• Must NOT be breastfeeding, pregnant or planning to become pregnant
Compensation: You may be compensated for your time and participation.
About: The study is designed to evaluate the efficacy, safety and tolerability of NDI-034858 in subjects with moderate to severe plaque psoriasis. The study will evaluate the plasma concentrations of the drug and explore the immune response to NDI-034858 in subjects.
The subject will come to the site on 8 occasions. During the treatment period, the medication or placebo will be taken orally every day for 12 weeks. The 12-week treatment period will be followed by a 4-week safety follow-up period.
Location: Orlando, FL
Indication: Urticaria
Sponsor: Teva Pharmaceuticals USA
PI: Christopher Chappel, MD
Intervention/Treatment: TEV-45779 and XOLAIR®️️️
Age: 18-75
Criteria:
• Has diagnosis of CIU refractory to H1 antihistamines for ≥3 months
• Does NOT have chronic urticaria with clearly defined underlying etiology
• Does NOT have other skin disease associated with itch
Compensation: You may be compensated for your time and participation
About: The purpose of the study is to compare the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability, and immunogenicity of TEV-45779 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment.
